Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib (MACS1760)

Share this content:
Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib (MACS1760)

Sponsors and Collaborators
Novartis Pharmaceuticals

Contact
Novartis Pharmaceuticals
+1(800)340-6843

Principal Investigator
Novartis Pharmaceuticals

ClinicalTrials.gov Identifier
NCT01514448

You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters